Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry

MLA

Yedid Elbez, et al. “Generalizability of the REDUCE-IT Trial and Cardiovascular Outcomes Associated with Hypertriglyceridemia among Patients Potentially Eligible for Icosapent Ethyl Therapy: An Analysis of the REduction of Atherothrombosis for Continued Health (REACH) Registry.” International Journal of Cardiology, vol. 340, Oct. 2021, pp. 96–104. EBSCOhost, https://doi.org/10.1016/j.ijcard.2021.08.031.

APA

Yedid Elbez, Peter W.F. Wilson, Sidney C. Smith, Fabien Picard, E. Magnus Ohman, Shinya Goto, Gregory Ducrocq, Deepak L. Bhatt, Kim A. Eagle, & Philippe Gabriel Steg. (2021). Generalizability of the REDUCE-IT trial and cardiovascular outcomes associated with hypertriglyceridemia among patients potentially eligible for icosapent ethyl therapy: An analysis of the REduction of Atherothrombosis for Continued Health (REACH) registry. International Journal of Cardiology, 340, 96–104. https://doi.org/10.1016/j.ijcard.2021.08.031

Chicago

Yedid Elbez, Peter W.F. Wilson, Sidney C. Smith, Fabien Picard, E. Magnus Ohman, Shinya Goto, Gregory Ducrocq, Deepak L. Bhatt, Kim A. Eagle, and Philippe Gabriel Steg. 2021. “Generalizability of the REDUCE-IT Trial and Cardiovascular Outcomes Associated with Hypertriglyceridemia among Patients Potentially Eligible for Icosapent Ethyl Therapy: An Analysis of the REduction of Atherothrombosis for Continued Health (REACH) Registry.” International Journal of Cardiology 340 (October): 96–104. doi:10.1016/j.ijcard.2021.08.031.